Roche to establish medical research hub in Singapore

Roche is likely to enter into a strategic alliance with Singapore’s scientific and medical instituti

The 'Hub for Translational Medicine' aims to enhance the understanding of how scientific advances from preclinical research can be transferred in practice to patients. Bringing together world-class expertise from Singapore's scientific and medical research institutions with Roche's capability in translational medicine and clinical development, this new centre will focus on expanding knowledge of disease biology to develop new personalised treatment approaches.

Jean-Jacques Garaud, global head of pharma research and early development at Roche, said: "Singapore's research institutions offer outstanding scientific excellence combined with state-of-the-art translational medicine facilities. The powerful combination of intellectual and technological capabilities together with outstanding government commitment at the heart of this collaboration will provide a unique opportunity to drive personalised healthcare."

Dr Beh Swan Gin, managing director of Singapore Economic Development Board, said: "We are delighted that Roche has chosen to work with Singapore in this pioneering public-private partnership that leverages on our network of biomedical sciences research institutes and academic medical centres. This collaboration will enable Roche to conduct multidisciplinary studies and generate important insights in disease biology to accelerate the drug discovery and development process."

George Radda, chairman of Biomedical Research Council, Agency for Science, Research and Technology (A*STAR), Singapore, said: "We are proud to partner Roche's new Hub for Translational Medicine in Singapore. Roche's decision to collaborate with Singapore's research institutes attests to the strong core biomedical research capabilities present here and reflects the attractiveness of Singapore as a choice biomedical research hub for impactful industry collaborations."

With an investment of 100m Swiss Francs, the new Hub will initially employ around 30 leading scientists. A joint steering committee, consisting of members from Roche and the Singapore institutes, will define the strategic direction of the alliance and oversee its research projects.